Cancer News

FDA Approves Venetoclax for Chronic and Small Lymphocytic Leukemia/Lymphoma With or Without 17 p Deletion, (06/25/2018)

The Food and Drug Administration granted regular approval to Venclexta (venetoclax) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Approval was based on a multicenter, open-label clinical trial of venclexta with rituximab (VEN+R) versus bendamustine with rituximab (B+R) …

Continue reading "FDA Approves Venetoclax for Chronic and Small Lymphocytic Leukemia/Lymphoma With or Without 17 p Deletion,"

Venclexta Significantly Reduces Cancer Progression in Chronic Lymphocytic Leukemia (03/22/2018)

CancerConnect News: Venclexta (venetoclax) plus Rituxan (rituximab) significantly reduces the risk of cancer progression or death at two years, compared with Treanda (bendustamine) plus Rituxan in the treatment of chronic lymphocytic leukemia that has recurred following prior therapies. These results were recently presented at the 59th annual meeting of the American Society of Hematology (ASH). …

Continue reading "Venclexta Significantly Reduces Cancer Progression in Chronic Lymphocytic Leukemia"

FDA Approves Imbruvica for First Line Treatment of Chronic Lymphocytic Leukemia (03/23/2016)

Learn more about other FDA Approvals for CLL here. Find more information on CLL here. The US Food and Drug Administration (FDA) approved Imbruvica® (ibrutinib) for first-line use in patients with chronic lymphocytic leukemia (CLL). The approval means that there is, for the first time, a chemotherapy-free option for initial treatment of CLL.1 Chronic lymphocytic … Continue reading "FDA Approves Imbruvica for First Line Treatment of Chronic Lymphocytic Leukemia"